PPH ETF Analysis: Pharmaceutical | NASDAQ
Healthcare Equity | NASDAQ, USA | Market Cap: 1.074m USD | 12M Return: 29.8% | US92189F6925 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 43.4M
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
The VanEck Pharmaceutical ETF (PPH) is a passively managed exchange-traded fund that seeks to track a pharmaceutical industry benchmark by investing at least 80% of its total assets in the securities comprising it. The underlying index comprises U.S. exchange-listed pharmaceutical companies through common stocks and depositary receipts, and may include medium-capitalization issuers as well as foreign companies listed on a U.S. exchange. The fund is structured as non-diversified, meaning it may hold a more concentrated portfolio than diversified ETFs.
The pharmaceutical sector is characterized by high research and development costs, long product development timelines, and revenue heavily dependent on patent protection and regulatory approvals from bodies such as the U.S. Food and Drug Administration. ETFs tracking narrow industry segments like pharmaceuticals typically employ either full replication or representative sampling strategies to deliver index-based exposure to investors seeking targeted sector bets rather than diversified market-wide holdings.
- GLP-1 drug sales surge lifts major pharma holdings
- Medicare drug price negotiations pressure pharma margins
- Patent expirations and biosimilar competition threaten revenue
As of November 11, 2026, the stock is trading at USD 121.59 with a total of 175,565 shares traded. Over the past week, the price has changed by +2.52%, over one month by +9.84%, over three months by +8.21% and over the past year by +29.84%.
Current recommended Stop Loss: 115.10 (which is 5.3% or 2.7 ATR below the current price).
Pharmaceutical has no consensus analysts rating.